Your session is about to expire
← Back to Search
Atezolizumab + IL-12 Gene Therapy for Non-Small Cell Lung Cancer
Study Summary
This trial is testing a new treatment for lung cancer that has progressed despite other treatments. The new treatment is a combination of atezolizumab and ADV/IL-12 gene therapy.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- It has been over 4 weeks since my last major surgery, radiation, or cancer treatment.I have not had a severe infection in the last 4 weeks.My heart pumps blood effectively.You must test negative for HIV.You have a disease that can be measured using specific guidelines.I haven't taken any immune-weakening drugs in the last 2 weeks.I am willing to provide tissue samples for the study.You are expected to live for at least 6 more months.My lung cancer has spread and was confirmed by a lab test.I have not had serious heart problems in the last 3 months.You have had serious allergic reactions to certain types of medications in the past.I am either male or female.I have not received a live vaccine in the last 4 weeks.I am 18 years old or older.I am fully active or restricted in physically strenuous activity but can do light work.I have had a previous transplant of stem cells or an organ.My tumor can be reached for treatment injections.I haven't taken any immune-boosting drugs in the last 4 weeks.You currently have or have had a condition that affects your immune system.My cancer has worsened despite initial immunotherapy.I don't have any health issues that would prevent me from taking a new drug.I have high calcium levels in my blood that are causing symptoms.I frequently need procedures to remove excess fluid from my chest or abdomen.I have a history of specific lung conditions without a known cause.I have active tuberculosis.I have had cancer spread to the lining of my brain and spinal cord.My cancer pain is not managed with current treatment.My blood and organs are functioning well.I have cancer that has spread to my brain or surrounding membranes.You are allergic to Chinese hamster ovary cell products or any part of the atezolizumab medicine.You are allergic to any part of the ADV/IL-12 treatment.I agree to either not have sex or use a condom.I have not had any other cancer in the last 2 years.You test negative for hepatitis B surface antigen (HBsAg) at screening.I am currently on medication for hepatitis B.I have previously received gene therapy.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Group 1: Atezolizumab and Interleukin-12 Gene Therapy
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has a research endeavor such as this ever been attempted before?
"At present, 350 studies concerning Atezolizumab and Interleukin-12 Gene Therapy are live in 74 countries across 1646 cities. The exploration first began in 2008 with a phase 2 drug approval trial sponsored by Hoffmann-La Roche. This study involved 720 participants and since then, 81 have been concluded successfully."
Has the FDA signed off on Atezolizumab and Interleukin-12 Gene Therapy?
"Due to the limited amount of clinical data available, Atezolizumab and Interleukin-12 Gene Therapy were assigned a score of 1 on our safety scale. This is consistent with it being an early Phase 1 trial."
What is the participation rate for this medical trial?
"Affirmative. The clinical trial website indicates that this research project is actively recruiting participants, having been posted on October 14th 2021 and most recently updated March 9th 2022. 16 patients are required to be enrolled from one location."
For what conditions is Atezolizumab and Interleukin-12 Gene Therapy commonly prescribed?
"Atezolizumab and Interleukin-12 Gene Therapy are primarily used to treat small cell lung cancer (sclc). However, these treatments can also be utilized for other malignant neoplasms, non-small cell lung carcinoma, and postoperative cases."
Are there any openings for people to join this clinical trial?
"Clinicaltrials.gov reports that the medical trial remains open and was initially posted on October 14th 2021, with its latest update being made on March 9th 2022."
Share this study with friends
Copy Link
Messenger